NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
STTK
Shattuck Labs, Inc.
There isn't enough reported data to score STTK yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STTK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
STTK's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
STTK PE Valuation
STTK has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STTK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STTK's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STTK on earnings quality, reporting a profit while its opponent remains loss making.
STTK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$0.46 |
| Q2 2026 | -$0.56 | +$0.65 |
| Q1 2026 | -$0.68 | +$0.71 |
| Q4 2025 | -$0.82 | +$0.67 |
| Q3 2025 | -$1.02 | +$0.51 |
| Q2 2025 | -$1.21 | +$0.64 |
| Q1 2025 | -$1.39 | +$0.54 |
| Q4 2024 | -$1.49 | +$0.56 |
STTK is still losing money, but far less than before: $0.56 per share over the past year, against $2.43 at its worst in late 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over STTK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
STTK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $1M | -67% |
| Q3 2024 | $3M | +337% |
| Q2 2024 | $1.6M | +705% |
| Q1 2024 | $1.1M | +1856% |
| Q4 2023 | $714K | +83% |
| Q3 2023 | $686K | +224% |
| Q2 2023 | $200K | +300% |
| Q4 2022 | $390K | -99% |
STTK's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -1072% | -474 points |
| Q3 2024 | -598% | +3571 points |
| Q2 2024 | -1427% | +9946 points |
| Q1 2024 | -1798% | +36204 points |
| Q4 2023 | -2654% | +4083 points |
| Q3 2023 | -4169% | +7732 points |
| Q2 2023 | -11374% | +43943 points |
| Q1 2023 | -38002% | N/A |
STTK's operating margin was −1072% last quarter, up 1583 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
STTK has the stronger cash trend. Its trailing FCF is up 29% versus its history, compared with NVO at down 14%.
STTK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.5M | -$8.5M |
| Q1 2026 | -$13.4M | -$1.4M |
| Q4 2025 | -$8.5M | +$8.9M |
| Q3 2025 | -$9M | +$7.1M |
| Q1 2025 | -$12M | +$4.1M |
| Q4 2024 | -$17.4M | +$2.1M |
| Q3 2024 | -$16.1M | +$643K |
| Q2 2024 | -$10.9M | +$8M |
STTK has burned cash in almost every quarter: −$48M over the past year, against −$56M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STTK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STTK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +17.5M shares |
| 1 year | +154% | +78.8M shares |
| 3 years | +206% | +87.3M shares |
| 5 years | +210% | +87.9M shares |
| Available history | +579% | +111M shares |
STTK has 130M diluted shares, up 154% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STTK Net Leverage
STTK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STTK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 10.1 | Oversold |
STTK's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STTK PE vs Healthcare Sector
STTK has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
STTK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.58 | 14% below |
| 20 week MA | $6.43 | 25% below |
| 50 week MA | $5.68 | 15% below |
| 100 week MA | $3.48 | 38% above |
| 200 week MA | $3.90 | 23% above |
STTK has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STTK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.4 | $57.6 | +198% |
| 2021 | $57.6 | $8.90 | -85% |
| 2022 | $8.90 | $2.41 | -73% |
| 2023 | $2.41 | $7.13 | +196% |
| 2024 | $7.13 | $1.24 | -83% |
| 2025 | $1.24 | $3.35 | +170% |
| 2026 YTD | $3.35 | $4.81 | +44% |
STTK has the edge over NVO on returns for 2026, with the stronger performance.